This Article Full Text (PDF) Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gaze, M N Articles by Mairs, R J Search for Related Content PubMed PubMed Citation Articles by Gaze, M N Articles by Mairs, R J

Pharmacokinetics and efficacy of ¹³¹I-meta-iodobenzylguanidine in two neuroblastoma xenografts

University of Glasgow Department of Radiation Oncology, Cancer Research Campaign Beatson Laboratories, Garscube Estate, Glasgow G61 1BD, UK

The pharmacokinetics, biodistribution and efficacy of the radiopharmaceutical ¹³¹I-meta-iodobenzylguanidine (¹³¹I-mIBG) were determined in murine xenografts of two human neuroblastoma cell lines, SK-N-SH and SK-N-BE(2c). These lines have similar capacities in vitro for active uptake of ¹³¹I-mIBG, but different radiobiological characteristics. Groups of four mice were killed after injection of ¹³¹I-mIBG, and retained radioactivity in the tumour and normal tissues was measured at 8, 16, 24 and 48 h. Within each type there was heterogeneity of tumour uptake, although average values were similar for both. The per cent injected dose per gram of tumour retained at 24 h was (mean and 95%confidence interval) 0.95 (0.67–1.23) for SK-N-SH and 0.76 (0.47–1.05) for SK-N-BE(2c). The growth of tumours in groups of seven animals following injection of 35, 70 or 105 MBq ¹³¹I-mIBG was compared with that of controls. The specific regrowth delay (median and 95% confidence intervals) caused by 105 MBq ¹³¹I-mIBG was 4.2 (0.9–5.9) in SK-N-SH and 5.6 (0–11.3) in SK-N-BE(2c) bearing mice. SK-N-BE(2c) xenografts were significantly more sensitive to external beam irradiation than SK-N-SH xenografts.

Received for publication June 23, 1993. Revision received October 5, 1993. Accepted for publication October 14, 1993.

This article has been cited by other articles:

				A. G. McCluskey, M. Boyd, S. C. Ross, E. Cosimo, A. M. Clark, W. J. Angerson, M. N. Gaze, and R. J. Mairs [131I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter Clin. Cancer Res., November 1, 2005; 11(21): 7929 - 7937. [Abstract] [Full Text] [PDF]